Back | Next |
home / stock / nnvc / nnvc message board
Subject | By | Source | When |
---|---|---|---|
"And as such, virtually worthless." | loanranger | investorshub | 06/30/2023 1:38:46 AM |
Randomized, no comparator....I take that to mean no | sunspotter | investorshub | 06/29/2023 10:09:02 PM |
OK,... sudden decent volume and up ~18%? What's | loanranger | investorshub | 06/29/2023 9:18:01 PM |
Would be good to see the trial endpoints | loanranger | investorshub | 06/29/2023 9:03:11 PM |
Mr. Market - he was apparently not at | drkazmd65 | investorshub | 06/29/2023 6:57:31 PM |
https://www.acnnewswire.com/press-release/english/84955/ | SnakeOil | investorshub | 06/29/2023 2:39:23 PM |
So at last,... a Phase I trial of | drkazmd65 | investorshub | 06/29/2023 2:24:56 PM |
OK,... sudden decent volume and up ~18%? | drkazmd65 | investorshub | 06/28/2023 7:17:27 PM |
MomentumIts trading | loanranger | investorshub | 06/27/2023 2:13:33 PM |
oh yeah news for the day | KMBJN | investorshub | 06/26/2023 8:10:43 AM |
Price gaining last trade up | loanranger | investorshub | 06/25/2023 9:55:21 AM |
It's amazing how committed bagholders are to the | arvitar | investorshub | 06/09/2023 9:22:13 PM |
No mention of Karveer..... | loanranger | investorshub | 05/31/2023 9:33:53 PM |
Oh goody,... Another conference presentation,.... At least there | drkazmd65 | investorshub | 05/31/2023 2:16:54 PM |
Adopted: PLAN OF CONVERSION | loanranger | investorshub | 05/26/2023 10:36:13 AM |
I see $NNVC is doing covid cides now. | JG36 | investorshub | 05/25/2023 10:15:03 PM |
One of the dumbest things I ever did | JG36 | investorshub | 05/25/2023 10:11:48 PM |
Once again $NNVC is well below 2 clams, | JG36 | investorshub | 05/24/2023 7:40:42 AM |
Phase I trials mostly are focused on 'safety' | drkazmd65 | investorshub | 05/16/2023 3:14:13 PM |
Looks like the trial in India will be | KMBJN | investorshub | 05/16/2023 2:54:43 PM |
News, Short Squeeze, Breakout and More Instantly...
SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on Form 10-Q for the fiscal second quarter ending December 31, 2023 with the Securi...
SHELTON, CT / ACCESSWIRE / February 1, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, explains that the demonstration of strong safety and tolerability of NV-CoV-2 o...
SHELTON, CT / ACCESSWIRE / January 29, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the healthy subjects part of the Phase 1a/1b Clinical Trial...